Therapeutic Lymphatic Vessel Regeneration
Therapeutic Lymphatic Vessel Regeneration
批准号:
9022162
负责人:
Feng Zhao
金额:
$46.5万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2019-06-30
关键词:
Academic Research Enhancement AwardsAnti-Inflammatory AgentsAnti-inflammatoryAutologousAxillaAxillary Lymph Node DissectionBiologicalBiomaterials ResearchCell AdhesionCellsChronicCicatrixCoculture TechniquesDependenceDiseaseDrainage procedureEdemaEffectivenessEngineeringEnvironmentExtracellular MatrixExtracellular Matrix ProteinsFibrosisForearmGenerationsGoalsGrowthIn VitroInjection of therapeutic agentInjuryIntramuscularLifeLymphLymph Node DissectionsLymphangiogenesisLymphaticLymphatic CapillariesLymphatic Endothelial CellsLymphatic vesselLymphedemaLymphoid TissueMediatingMentorshipMesenchymal Stem CellsMichiganModelingNatural regenerationObstructionOxygenPhysiologicalPlayProductionPropertyQuality of lifeRattusRecordsResearchResearch AssistantRiskRoleSiteStagingStem cellsSwellingTechnologyTherapeuticTissue EngineeringTissuesTrainingTraining SupportTransplanted tissueVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DVascular Endothelial Growth FactorsWomanWound Healingarmbasecell motilitycellular engineeringcytokineeffective therapyexperienceimplantationimprovedin vivoin vivo regenerationinjuredinterstitiallymph flowmalignant breast neoplasmnanofiberpublic health relevanceregenerativerestorationscaffoldself-renewalstem cell therapystemnesstissue regenerationundergraduate researchundergraduate student
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Secondary lymphedema is a lifelong and occasionally life-threatening disease that often occurs as a consequence of axillary clearance for breast cancer. Regeneration of lymphatic tissues and restoration of lymph flow through a fibrotic scar are two basic essentials for the treatment of secondary lymphedema. Mesenchymal stem cells (MSCs) hold great therapeutic potential due to their effectiveness in stimulating host tissue regeneration via secreting numerous pro-regenerative factors dependent on the specific demands of the type and stage of injury. However, MSCs tend to differentiate and lose their self-renewal ability during the ex vivo expansion. Also, direct delivery of MSCs through injection will lose the function of extracellular matrix (ECM) proteins, which also play an important role in
the lymphatic tissue regeneration and which tend to be absent in fibrotic tissues. We propose to use MSCs to fabricate both MSC cell sheet fragments as well as a completely biological tissue-engineered lymphtic collecting vessel (TELCV) under physiologically low oxygen tension, which can effectively promote the ECM production, and maintain the stemness of MSCs and thus their regenerative factor secreting capacity and differentiation ability. Our central hypothesis is that the local administration of MSC fragments, combined with a MSC-based TELCV, will significantly reduce lymphatic edema and improve lymphatic regeneration via the in-site formation of functional lymphatic vasculature and the restoration of lymphatic drainage. The proposed study applies advanced stem cell engineering technology in lymphedema treatment. Upon completion, it will provide an effective treatment of secondary lymphedema, and thereby hold great potential in significantly improving the life quality of women suffering from lymphedema. This Academic Research Enhancement Award (AREA) will also allow us to train undergraduate students with hands-on experience in stem cell and tissue engineering research.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.7150/thno.29552
发表时间:
2019-01-01
期刊:
THERANOSTICS
影响因子:
12.4
作者:
[Qian, Zichen, Sharma, Dhavan, Zhao, Feng]
通讯作者:
Zhao, Feng
DOI:
10.1016/j.bioactmat.2019.02.002
发表时间:
2019-12-01
期刊:
BIOACTIVE MATERIALS
影响因子:
18.9
作者:
[Sharma, Dhavan, Jia, Wenkai, Zhao, Feng]
通讯作者:
Zhao, Feng
DOI:
10.1007/7651_2018_142
发表时间:
2019-01-01
期刊:
SKIN STEM CELLS, 2 EDITION
影响因子:
--
作者:
[Chen, Lei, Radke, Daniel, Zhao, Feng]
通讯作者:
Zhao, Feng
DOI:
10.7150/thno.17031
发表时间:
2017
期刊:
Theranostics
影响因子:
12.4
作者:
[Chen L, Xing Q, Zhai Q, Tahtinen M, Zhou F, Chen L, Xu Y, Qi S, Zhao F]
通讯作者:
Zhao F
DOI:
10.1002/adhm.201601333
发表时间:
2017-05
期刊:
Advanced healthcare materials
影响因子:
10
作者:
[Xing Q, Qian Z, Tahtinen M, Yap AH, Yates K, Zhao F]
通讯作者:
Zhao F
共 6 条
Engineered Anisotropic and Vascularized Human Cardiac Patch
-
批准号:10448375
-
项目类别:
-
资助金额:$37.15万
-
财政年份:2021
-
负责人:Feng Zhao
-
依托单位:
Engineered Anisotropic and Vascularized Human Cardiac Patch
-
批准号:10652538
-
项目类别:
-
资助金额:$36.59万
-
财政年份:2021
-
负责人:Feng Zhao
-
依托单位:
Engineered Anisotropic and Vascularized Human Cardiac Patch
-
批准号:10378333
-
项目类别:
-
资助金额:$34.45万
-
财政年份:2021
-
负责人:Feng Zhao
-
依托单位:
Engineered Anisotropic and Vascularized Human Cardiac Patch
-
批准号:9886725
-
项目类别:
-
资助金额:$34.74万
-
财政年份:2020
-
负责人:Feng Zhao
-
依托单位:
Development of Off-the-shelf Completely Biological Small-Diameter Blood Vessel wi
-
批准号:8497217
-
项目类别:
-
资助金额:$41.01万
-
财政年份:2013
-
负责人:Feng Zhao
-
依托单位:
海外基金